Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance. Poeschel V, et al. Among authors: merli f. Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9. Lancet. 2019. PMID: 31868632 Clinical Trial.
Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma.
Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, Liso V, Tabilio A, Saglio G, Vinci G, Brugiatelli M, Dastoli G; GISL. Sacchi S, et al. Among authors: merli f. Haematologica. 2001 Sep;86(9):951-8. Haematologica. 2001. PMID: 11532623 Free article. Clinical Trial.
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
Lombardo M, Morabito F, Merli F, Molica S, Cavanna L, Sacchi S, Broglia C, Angrilli F, Ilariucci F, Stelitano C, Luisi D, Bertè R, Luminari S, Federico M, Brugiatelli M; GISL. Lombardo M, et al. Among authors: merli f. Leuk Lymphoma. 2002 Sep;43(9):1795-801. doi: 10.1080/1042819021000006457. Leuk Lymphoma. 2002. PMID: 12685834
Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi.
Gobbi PG, Broglia C, Merli F, Dell'Olio M, Stelitano C, Iannitto E, Federico M, Bertè R, Luisi D, Molica S, Cavalli C, Dezza L, Ascari E. Gobbi PG, et al. Among authors: merli f. Cancer. 2003 Dec 1;98(11):2393-401. doi: 10.1002/cncr.11807. Cancer. 2003. PMID: 14635074 Free article.
Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi.
Merli F, Bertini M, Luminari S, Mozzana R, Bertè R, Trottini M, Stelitano C, Botto B, Pizzuti M, Quintana G, De Paoli A, Federico M; Intergruppo Italiano Linfomi. Merli F, et al. Haematologica. 2004 Aug;89(8):973-8. Haematologica. 2004. PMID: 15339681 Free article. Clinical Trial.
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M; Intergruppo Italiano Linfomi. Gobbi PG, et al. Among authors: merli f. J Clin Oncol. 2005 Dec 20;23(36):9198-207. doi: 10.1200/JCO.2005.02.907. Epub 2005 Sep 19. J Clin Oncol. 2005. PMID: 16172458 Clinical Trial.
The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL).
Gobbi PG, Broglia C, Valentino F, Mammi C, Lombardo M, Merli F, Luminari S, Polimeno G, Riezzo A, Lambelet P, Rovati A, Corazza GR, Federico M; Gruppo Italiano Studio Linfomi. Gobbi PG, et al. Among authors: merli f. Ann Oncol. 2006 Apr;17(4):676-82. doi: 10.1093/annonc/mdl002. Epub 2006 Jan 30. Ann Oncol. 2006. PMID: 16446317 Free article. Clinical Trial.
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.
Federico M, Luminari S, Gobbi PG, Sacchi S, Di Renzo N, Lombardo M, Merli F, Baldini L, Stelitano C, Partesotti G, Polimeno G, Montanini A, Mammi C, Brugiatelli M. Federico M, et al. Among authors: merli f. Eur J Haematol. 2006 Mar;76(3):217-29. doi: 10.1111/j.1600-0609.2005.00609.x. Eur J Haematol. 2006. PMID: 16451396 Clinical Trial.
184 results